{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:42Z","timestamp":1786987542055,"version":"build-2736575974"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104938","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:49:57Z","timestamp":1757771397000},"page":"104938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Beyond the blood-brain barrier: Intranasal vaccines in cancer immunotherapy"],"prefix":"10.1016","volume":"216","author":[{"given":"Anju","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vajrashree","family":"P.S.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"G.S.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.Trideva","family":"Sastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"A.R.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinamyee U.","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balamuralidhara","family":"V.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104938_bib1","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.2174\/138161210791164108","article-title":"Potential of nanoparticulate drug delivery systems by intranasal administration","volume":"16","author":"Ali","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.critrevonc.2025.104938_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/vaccines12040409","article-title":"Design and characterization of a new formulation for the delivery of COVID-19-mRNA vaccine to the nasal mucosa","volume":"12","author":"Altay Benetti","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2025.104938_bib3","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/s41467-025-59353-6","article-title":"An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models","volume":"16","author":"Anthi","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104938_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-023-01780-y","article-title":"Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant shigella: a flexible platform technology","volume":"21","author":"Baruah","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2025.104938_bib6","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1080\/21645515.2016.1197453","article-title":"Dendritic cell vaccination in melanoma patients: from promising results to future perspectives","volume":"12","author":"Boudewijns","year":"2016","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.critrevonc.2025.104938_bib7","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.4049\/jimmunol.174.10.6292","article-title":"Electroporation as a \u201cPrime\/Boost\u201d strategy for naked DNA vaccination against a tumor antigen","volume":"174","author":"Buchan","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog. Exp. Tumor Res."},{"key":"10.1016\/j.critrevonc.2025.104938_bib9","article-title":"Potentials of saponins-based adjuvants for nasal vaccines","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/17425247.2025.2464714","article-title":"Bringing intranasal drug delivery for malignancies in the brain to market","volume":"22","author":"Chen","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.critrevonc.2025.104938_bib11","unstructured":"Clinical evaluation of new vaccines - Scientific guideline | European Medicines Agency (EMA) [WWW Document], n.d. URL \u3008https:\/\/www.ema.europa.eu\/en\/clinical-evaluation-new-vaccines-scientific-guideline\u3009 (accessed 8.21.25)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.it.2015.02.006","article-title":"Immune-mediated mechanisms influencing the efficacy of anticancer therapies","volume":"36","author":"Coffelt","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2008.09.005","article-title":"Nanoparticles for nasal vaccination","volume":"61","author":"Csaba","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2025.104938_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615240","article-title":"Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments","volume":"11","author":"Cuzzubbo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615240","article-title":"Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments","volume":"11","author":"Cuzzubbo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ni0303-201","article-title":"Observing the invisible: successful tumor immunity in humans","volume":"4","author":"Darnell","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the number of men living with metastatic prostate cancer in the United States","volume":"32","author":"Devasia","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.critrevonc.2025.104938_bib18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104938_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010207","article-title":"Recent advances in intranasal liposomes for drug, gene, and vaccine delivery","volume":"15","author":"Duong","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2025.104938_bib22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.46747\/cfp.6810751","article-title":"Vaccination considerations for patients receiving cancer therapy","volume":"68","author":"Einarsson","year":"2022","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.critrevonc.2025.104938_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1567116","article-title":"Artificial intelligence in vaccine research and development: an umbrella review","volume":"16","author":"El Arab","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib24","doi-asserted-by":"crossref","unstructured":"Elfatimi, E., Lekbach, Y., Prakash, S., Lbachir Benmohamed, 2025. Artificial Intelligence and machine learning in the development of vaccines and immunotherapeutics yesterday, today, and tomorrow.","DOI":"10.3389\/frai.2025.1620572"},{"key":"10.1016\/j.critrevonc.2025.104938_bib25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.vaccine.2017.01.074","article-title":"GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth","volume":"35","author":"Esquerr\u00e9","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2025.104938_bib26","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2174\/092986712800099811","article-title":"Induction of abscopal Anti-Tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies","volume":"19","author":"Frey","year":"2012","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.critrevonc.2025.104938_bib28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/jnci\/djac158","article-title":"Estimation of the number of individuals living with metastatic cancer in the United States","volume":"114","author":"Gallicchio","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.104938_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104938_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.104938_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-024-05676-9","article-title":"Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis","volume":"22","author":"Garai","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104938_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1634\/theoncologist.2019-0608","article-title":"A phase I trial using a multitargeted recombinant adenovirus 5 (CEA\/MUC1\/Brachyury)-Based immunotherapy vaccine regimen in patients with advanced cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104938_bib33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/odi.14196","article-title":"Risk factors for head and neck cancer in more and less developed countries: analysis from the INHANCE consortium","volume":"29","author":"Goyal","year":"2023","journal-title":"Oral. Dis."},{"key":"10.1016\/j.critrevonc.2025.104938_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4103\/0019-5049.190618","article-title":"Literature search for research planning and identification of research problem","volume":"60","author":"Grewal","year":"2016","journal-title":"Indian J. Anaesth."},{"key":"10.1016\/j.critrevonc.2025.104938_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2024.04.047","article-title":"Oral targeted drug delivery to post-gastrointestinal sites","volume":"370","author":"Han","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2025.104938_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.12.050","article-title":"Advances in targeted therapy for unresectable melanoma: new drugs and combinations","volume":"359","author":"Hao","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104938_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrc.2017.61","article-title":"Tumour vaccines: personal training by vaccination","volume":"17","author":"Harjes","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104938_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11100540","article-title":"Liposomal formulations for Nose-to-Brain delivery: recent advances and future perspectives","volume":"11","author":"Hong","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2025.104938_bib39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fchem.2020.00601","article-title":"Emerging adjuvants for cancer immunotherapy","volume":"8","author":"Hu","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.critrevonc.2025.104938_bib40","first-page":"37","article-title":"Afatinib reverses EMT via inhibiting CD44-Stat3 axis to promote radiosensitivity in nasopharyngeal carcinoma","volume":"16","author":"Huang","year":"2022","journal-title":"Pharmaceuticals 2023"},{"key":"10.1016\/j.critrevonc.2025.104938_bib41","unstructured":"ICH Official web site: ICH [WWW Document], n.d. URL \u3008https:\/\/www.ich.org\/\u3009 (Accessed 8.20.25)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1684\/bdc.2013.1771","article-title":"Immune-checkpoints: the new anti-cancer immunotherapies","volume":"100","author":"Ileana","year":"2013","journal-title":"Bull Cancer"},{"key":"10.1016\/j.critrevonc.2025.104938_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery - possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2025.104938_bib44","unstructured":"Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer - PMC [WWW Document], n.d. URL \u3008https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4085883\/\u3009 (Accessed 7.26.24)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/17425247.2015.1044435","article-title":"Nasal and pulmonary vaccine delivery using particulate carriers","volume":"12","author":"Jia","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.critrevonc.2025.104938_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104938_bib47","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib48","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.vaccine.2023.05.011","article-title":"Advances in intranasal vaccine delivery: a promising non-invasive route of immunization","volume":"41","author":"Kehagia","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2025.104938_bib49","article-title":"Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by trans-airway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10","volume":"17","author":"Kimoto","year":"2023","journal-title":"Influenza Other Respir. Virus"},{"key":"10.1016\/j.critrevonc.2025.104938_bib50","article-title":"Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by trans-airway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10","volume":"17","author":"Kimoto","year":"2023","journal-title":"Influenza Other Respir. Virus"},{"key":"10.1016\/j.critrevonc.2025.104938_bib51","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104938_bib52","doi-asserted-by":"crossref","first-page":"1357217","DOI":"10.3389\/fimmu.2024.1357217","article-title":"Personalized cancer vaccine design using AI-powered technologies","volume":"15","author":"Kumar","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib53","first-page":"1","article-title":"Intranasal prime-boost RNA vaccination elicits potent t cell response for lung cancer therapy","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104938_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105900","article-title":"Double synergic chitosan-coated poly (lactic-co-glycolic) acid nanospheres loaded with nucleic acids as an intranasally administered vaccine delivery system to control the infection of foot-and-mouth disease virus","volume":"226","author":"Li","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.critrevonc.2025.104938_bib55","article-title":"A clinical prognostic model related to t cells based on machine learning for predicting the prognosis and immune response of ovarian cancer","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2025.104938_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6750-10-77","article-title":"Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis","volume":"10","author":"Lorenzi","year":"2010","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6750-10-77","article-title":"Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis","volume":"10","author":"Lorenzi","year":"2010","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1871520615666150824153523","article-title":"The immune system in cancer prevention, development and therapy","volume":"16","author":"M. Candeias","year":"2016","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.104938_bib59","unstructured":"Maciej Serda, Becker, F.G., Cleary, M., Team, R.M., Holtermann, H., The, D., Agenda, N., Science, P., Sk, S.K., Hinnebusch, R., Hinnebusch A R., Rabinovich, I., Olmert, Y., Uld, D.Q.G.L.Q., Ri, W.K.H.U., Lq, V., Frxqwu, W.K.H., Zklfk, E., Edvhg, L. V, Wkh, R.Q., Becker, F.G., Aboueldahab, N., Khalaf, R., De Elvira, L.R., Zintl, T., Hinnebusch, R., Karimi, M., Mousavi Shafaee, S.M., O \u2019driscoll, D., Watts, S., Kavanagh, J., Frederick, B., Norlen, T., O\u2019Mahony, A., Voorhies, P., Szayna, T., Spalding, N., Jackson, M.O., Morelli, M., Satpathy, B., Muniapan, B., Dass, M., Katsamunska, P., Pamuk, Y., Stahn, A., Commission, E., Piccone, T.E.D., Annan, Mr.K., Djankov, S., Reynal-Querol, M., Couttenier, M., Soubeyran, R., Vym, P., Prague, E., World Bank, Bodea, C., Sambanis, N., Florea, A., Florea, A., Karimi, M., Mousavi Shafaee, S.M., Spalding, N., Sambanis, N., \u0641\u0627\u0637\u0645\u06cc, \u062d., 2013. Synteza i aktywno\u015b\u0107 biologiczna nowych analog\u00f3w tiosemikarbazonowych chelator\u00f3w \u017celaza. Uniwersytet \u015bl\u0105ski 7, 343\u2013354. 10.2\/JQUERY.MIN.JS."},{"key":"10.1016\/j.critrevonc.2025.104938_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111882","article-title":"Current progress and future perspectives of RNA-Based cancer vaccines: a 2025 update","volume":"17","author":"Magoola","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104938_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.757761","article-title":"Nanocarriers-Assisted Needle-Free vaccine delivery through oral and intranasal transmucosal routes: a novel therapeutic conduit","volume":"12","author":"Mangla","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.104938_bib62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib63","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the United States","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.critrevonc.2025.104938_bib64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00281-011-0246-z","article-title":"Contribution of the immune system to the chemotherapeutic response","volume":"33","author":"McDonnell","year":"2011","journal-title":"Semin Immunopathol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nature23093","article-title":"Cancer: precision T-cell therapy targets tumours","volume":"547","author":"Melief","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104938_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib68","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J. Intern Med"},{"key":"10.1016\/j.critrevonc.2025.104938_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1228148","article-title":"The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs","volume":"14","author":"Namiot","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.104938_bib70","doi-asserted-by":"crossref","first-page":"1438041","DOI":"10.3389\/fmed.2024.1438041","article-title":"Evaluation of the review models and approval timelines of authorities participating in the east African Medicine regulatory harmonisation initiative: alignment and strategies for moving forward","volume":"11","author":"Ngum","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.critrevonc.2025.104938_bib71","unstructured":"Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals | FDA [WWW Document], n.d. URL \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonclinical-evaluation-immunotoxic-potential-pharmaceuticals\u3009 (Accessed 8.21.25)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib72","unstructured":"Non-clinical evaluation of vaccines [WWW Document], n.d. URL \u3008https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/norms-and-standards\/vaccine-standardization\/non-clinical-evaluation-of-vaccines?utm_source=chatgpt.com\u3009 (Accessed 8.25.25)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104938_bib74","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104938_bib75","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104938_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627932","article-title":"Cancer vaccines, adjuvants, and delivery systems","volume":"12","author":"Paston","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104938_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep05128","article-title":"Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity","volume":"4","author":"Phua","year":"2014","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104938_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep05128","article-title":"Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity","volume":"4","author":"Phua","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104938_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/srep05128","article-title":"Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity","volume":"4","author":"Phua","year":"2014","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104938_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep05128","article-title":"Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity","volume":"4","author":"Phua","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104938_bib81","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","article-title":"Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants","volume":"19","author":"Pizza","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2025.104938_bib82","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1073\/pnas.1620194114","article-title":"Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic t cells","volume":"114","author":"Pizzolla","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.104938_bib83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clon.2007.10.011","article-title":"The immune system - is it relevant to cancer development, progression and treatment?","volume":"20","author":"Prestwich","year":"2008","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib84","unstructured":"Programmable Intrathecal Opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf [WWW Document], n.d. URL https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK74528\/ (Accessed 7.26.24)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2025.104938_bib86","first-page":"279","article-title":"Nasal vaccine delivery","author":"Ramvikas","year":"2016","journal-title":"Micro Nanotechnol. Vaccin. Dev."},{"key":"10.1016\/j.critrevonc.2025.104938_bib87","unstructured":"Recent Advances in Cancer Therapy: An overview - PubMed [WWW Document], n.d. URL https:\/\/pubmed.ncbi.nlm.nih.gov\/20214614\/ (accessed 7.26.24)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib88","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2007.06.009","article-title":"Tumor immunoediting and immunosculpting pathways to cancer progression","volume":"17","author":"Reiman","year":"2007","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib89","first-page":"1180","article-title":"Review of intranasal active pharmaceutical ingredient delivery systems","volume":"17","author":"Safarov","year":"2024","journal-title":"Pharmaceuticals 2024"},{"key":"10.1016\/j.critrevonc.2025.104938_bib90","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104938_bib91","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/Testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol. Invest"},{"key":"10.1016\/j.critrevonc.2025.104938_bib92","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000366431","article-title":"The immune system - how does anti-tumor immunity arise\u00a0?","volume":"37","author":"Sankawa","year":"2014","journal-title":"Oncol. Res Treat."},{"key":"10.1016\/j.critrevonc.2025.104938_bib93","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104938_bib94","first-page":"542","article-title":"Strategies of breast cancer treatment devised on the basis on biological subtype determination","volume":"57","author":"Semiglazov","year":"2011","journal-title":"Vopr. Onkol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib95","unstructured":"Serda, M., Becker, F.G., Cleary, M., Team, R.M., Holtermann, H., The, D., Agenda, N., Science, P., Sk, S.K., Hinnebusch, R., A, R.H., Rabinovich, I., Olmert, Y., Uld, D.Q.G.L.Q., Ri, W.K.H.U., Lq, V., Frxqwu, W.K.H., Zklfk, E., Edvhg, L.V., Wkh, R.Q., Becker, F.G., Aboueldahab, N., Khalaf, R., Elvira, L.R. De, Zintl, T., Hinnebusch, R., Karimi, M., Shafaee, S.M.M., \u2019driscoll, D.O., Watts, S., Kavanagh, J., Frederick, B., Norlen, T., O\u2019Mahony, A., Voorhies, P., Szayna, T., Spalding, N., Jackson, M.O., Morelli, M., Satpathy, B., Muniapan, B., Dass, M., Katsamunska, P., Pamuk, Y., Stahn, A., Commission, E., Piccone, T.E.D., Annan, Mr.K., Djankov, S., Reynal-Querol, M., Couttenier, M., Soubeyran, R., Vym, P., Prague, E., Bank, W., Bodea, C., Sambanis, N., Florea, A., Florea, A., Karimi, M., Shafaee, S.M.M., Spalding, N., Sambanis, N., \u0641\u0627\u0637\u0645\u06cc, \u062d., 2013. Synteza i aktywno\u015b\u0107 biologiczna nowych analog\u00f3w tiosemikarbazonowych chelator\u00f3w \u017celaza. Uniwersytet \u015bl\u0105ski 7, 343\u2013354. 10.2\/JQUERY.MIN.JS."},{"key":"10.1016\/j.critrevonc.2025.104938_bib96","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104938_bib97","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1211\/jpp.60.8.0009","article-title":"Antiangiogenics and radiotherapy","volume":"60","author":"Shannon","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020259","article-title":"Intranasal therapeutic peptide vaccine promotes efficient induction and trafficking of cytotoxic t cell response for the clearance of HPV vaginal tumors","volume":"8","author":"Sierra","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2025.104938_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020259","article-title":"Intranasal therapeutic peptide vaccine promotes efficient induction and trafficking of cytotoxic t cell response for the clearance of HPV vaginal tumors","volume":"8","author":"Sierra","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2025.104938_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020259","article-title":"Intranasal therapeutic peptide vaccine promotes efficient induction and trafficking of cytotoxic t cell response for the clearance of HPV vaginal tumors","volume":"8","author":"Sierra","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2025.104938_bib101","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/vaccines12121449","article-title":"Vaccination after haematopoietic stem cell transplant: a review of the literature and proposed vaccination protocol","volume":"12","author":"Silva-Pinto","year":"2024","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104938_bib102","first-page":"1075","article-title":"Advances in vaccine adjuvants","volume":"17","author":"Singh","year":"1999","journal-title":"Nat. Biotechnol. 1999"},{"key":"10.1016\/j.critrevonc.2025.104938_bib103","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/vaccines12020191","article-title":"Vaccine strategies to elicit mucosal immunity","volume":"12","author":"Song","year":"2024","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104938_bib104","unstructured":"Study Details | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | ClinicalTrials.gov [WWW Document], n.d. URL \u3008https:\/\/clinicaltrials.gov\/study\/NCT04039230\u3009 (Accessed 7.8.25)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4251\/wjgo.v7.i12.492","article-title":"Targeting cancer testis antigens for biomarkers and immunotherapy in colorectal cancer: current status and challenges","volume":"7","author":"Suri","year":"2015","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib106","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/pharmaceutics14051073","article-title":"Different methods and formulations of drugs and vaccines for nasal administration","volume":"14","author":"Tai","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2025.104938_bib107","first-page":"25","article-title":"Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders","author":"Ul Islam","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2025.104938_bib108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161210789941847","article-title":"Recent advances in cancer therapy: an overview","volume":"16","author":"Urruticoechea","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104938_bib109","first-page":"1","article-title":"Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants","volume":"10","author":"Vasilev","year":"2025","journal-title":"npj Vaccin. 2025"},{"key":"10.1016\/j.critrevonc.2025.104938_bib110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from t cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib111","unstructured":"What Is Cancer? - NCI [WWW Document], n.d.https:\/\/www.cancer.gov\/about-cancer\/understanding\/what-is-cancer (Accessed 7.26.24)."},{"key":"10.1016\/j.critrevonc.2025.104938_bib112","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/cgt.2012.55","article-title":"A Non-oncogenic HPV 16 E6\/E7 vaccine enhances treatment of HPV expressing tumors","volume":"19","author":"Wieking","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2025.104938_bib113","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cllc.2017.02.007","article-title":"Non\u2013small cell lung cancer as a second primary among patients with previous malignancy: who is at risk?","volume":"18","author":"Wu","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2025.104938_bib114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02786362","article-title":"Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system","volume":"16","author":"Wu","year":"1997","journal-title":"Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104938_bib115","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1016\/j.apsb.2024.08.026","article-title":"Respiratory delivered vaccines: current status and perspectives in rational formulation design","volume":"14","author":"Wu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2025.104938_bib116","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jconrel.2024.01.053","article-title":"Advances and future perspectives of intranasal drug delivery: a scientometric review","volume":"367","author":"Xu","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2025.104938_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121180","article-title":"Intranasal vaccine: factors to consider in research and development","volume":"609","author":"Xu","year":"2021","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104938_bib118","article-title":"Current status and future of cancer vaccines: a bibliographic study","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2025.104938_bib119","article-title":"Nanotechnology-driven advances in intranasal vaccine delivery systems against infectious diseases","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104938_bib120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104938_bib121","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2025.104966","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:06:28Z","timestamp":1767387988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":121,"alternative-id":["S1040842825003269"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104938","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the blood-brain barrier: Intranasal vaccines in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104938"}}